Kosgei, Jackline
Gimnig, John E.
Moshi, Vincent
Omondi, Seline
McDermott, Daniel P.
Donnelly, Martin J.
Ouma, Collins
Abong’o, Bernard
Ochomo, Eric
Funding for this research was provided by:
Bill and Melinda Gates Foundation (INV-007509, INV-007509, INV-007509)
Foreign Commonwealth and Development Office (30041-105, 30041-105)
Article History
Received: 28 August 2023
Accepted: 11 March 2024
First Online: 16 March 2024
Declarations
:
: The study was approved by the scientific and ethics review unit (SERU) of the Kenya Medial Research Institute (protocol number KEMRI/SERU/CGHR/123/3613) and by Institutional Review Board of the US Centers for Disease Control and Prevention (IRB# 7112). Written informed consent was obtained from all HLC collectors. The HLC collectors were given mefloquine malaria prophylaxis (Cheplapharm Arzneimittel GmbH, Ziegelhof 24, 17,489 Greifswald, Germany) and regularly tested for malaria. The prophylaxis treatment started 1 week before collections began and were given repeat doses once every week through the collection period, until 4 weeks after collections ended. Verbal consent was sought from the compound head to use light traps and Prokopack aspiration in their compounds.
: Not applicable.